Aryx Therapeutics Long Term Debt

Aryx Therapeutics (ARYX) currently reports a long-term debt of $5.5M as of September 2010. That compares with $6.4M in the prior-year period — down 13.7% year over year. Use the charts on this page to explore Aryx Therapeutics's long-term debt history and peer comparisons.

Aryx Therapeutics's long-term debt decreased from $6.4M to $5.5M — a 13.7% year-over-year decrease (period ending September 2010). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Aryx Therapeutics reported $5.5M in long-term debt as of September 2010. That compares with $6.4M in the prior-year period — down 13.7% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $5.5M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Aryx Therapeutics, and consider following ARYX for alerts when major investors trade the stock.

Aryx Therapeutics is classified in the Healthcare sector. On long-term debt, it currently shows $5.5M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ARYX with unrelated industries.